Browsing Tag
Oncology
317 posts
Can Namodenoson overcome immunotherapy resistance in advanced pancreatic adenocarcinoma?
Can-Fite BioPharma Ltd. advances Namodenoson into Phase 2b pancreatic cancer testing. Discover what this means for immunotherapy economics.
What the latest ALICE-2 and FRIDA trial results reveal about iadademstat’s AML potential
What do the latest ALICE-2 and FRIDA trial results reveal about iadademstat’s AML potential? Explore the strategic and market implications now.
Why ESR1 mutation targeting is critical in metastatic breast cancer treatment
FDA approves VEPPANU. Discover why ESR1 mutation targeting is reshaping metastatic breast cancer treatment and what it means next.
Arvinas wins first FDA-approved PROTAC as ARVN stock tests investor patience
PROTAC drugs finally have FDA validation. Arvinas now faces the harder question: can VEPPANU become a commercial oncology asset?
Why TROP2 ADC competition may hinge on payload differentiation after AKTX-101 data
Find out how AKTX-101 could reshape TROP2 ADC competition and what it means for oncology investors and strategy.
Why overcoming VEGF TKI resistance could reshape the treatment algorithm in clear cell renal cell carcinoma
Can overcoming VEGF resistance reshape kidney cancer treatment? Explore what Kura Oncology’s latest data means for markets and strategy.
Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Antengene (SEHK: 6996.HK) presents ATG-125, ATG-106, and ATG-112 preclinical data at AACR 2026. Read what the results mean for its pipeline strategy.
Is DLL3 becoming the most strategic biomarker target in neuroendocrine oncology?
Can dual DLL3 targeting improve SCLC outcomes? Read PDN’s deep analysis of the Boehringer Ingelheim and Zai Lab collaboration today.
How CLR 125 may test the limits of precision radiopharmaceutical therapy in solid tumors
Could CLR 125 redefine precision radiopharmaceutical therapy in solid tumors? Read what this means for Cellectar Biosciences, Inc. and oncology markets.
Massive Bio study shows AI clinical trial matching can work at real-world oncology scale
Massive Bio says its AI matched cancer patients to trials 4x faster in real-world practice. Read why this matters for oncology, sponsors, and care access.